Tags

Type your tag names separated by a space and hit enter

The clinical outcomes of selenium supplementation on critically ill patients: A meta-analysis of randomized controlled trials.
Medicine (Baltimore). 2019 May; 98(20):e15473.M

Abstract

PURPOSE

Selenium supplementation is a potentially promising adjunctive therapy for critically ill patients, but the results are controversy among studies. Accordingly, we performed this meta-analysis to more clearly detect the efficacy and safety of selenium supplementation on critically ill patients.

METHODS

Systematic literature retrieval was carried out to obtain RCTs on selenium supplementation for critically ill patients up to August 2017. Data extraction and quality evaluation of these studies were performed by 2 investigators. Statistical analyses was performed by RevMan 5.3. Trial sequential analysis (TSA) was conducted to control the risks of type I and type II errors and calculate required information size (RIS).

RESULTS

Totally 19 RCTs involving 3341 critically ill patients were carried out in which 1694 participates were in the selenium supplementation group, and 1647 in the control. The aggregated results suggested that compared with the control, intravenous selenium supplement as a single therapy could decrease the total mortality (RR = 0.86, 95% CI: 0.78-0.95, P = .002, TSA-adjusted 95% CI = 0.77-0.96, RIS = 4108, n = 3297) and may shorten the length of stay in hospital (MD -2.30, 95% CI -4.03 to -0.57, P = .009), but had no significant treatment effect on 28-days mortality (RR = 0.96, 95% CI: 0.85-1.09, P = .54) and could not shorten the length of ICU stay (MD -0.15, 95% CI -1.68 to 1.38, P = .84) in critically ill patients. Our results also showed that selenium supplementation did not increase incidence of drug-induced side effect compared with the control (RR 1.04, 95% CI 0.83 to 1.30, P = .73).

CONCLUSIONS

The current evidence suggests that the use of selenium could reduce the total mortality, and TSA results showed that our outcome is reliable and no more randomized controlled trials are needed. But selenium supplementation might have no effect on reducing 28-days mortality as well as the incidence of new infections, or on length of stay in ICU or mechanical ventilation. However, the results should be used carefully because of potential limitations.

Authors+Show Affiliations

Department of Critical Care Medicine, Chinese PLA General Hospital, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

31096444

Citation

Zhao, Yan, et al. "The Clinical Outcomes of Selenium Supplementation On Critically Ill Patients: a Meta-analysis of Randomized Controlled Trials." Medicine, vol. 98, no. 20, 2019, pp. e15473.
Zhao Y, Yang M, Mao Z, et al. The clinical outcomes of selenium supplementation on critically ill patients: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(20):e15473.
Zhao, Y., Yang, M., Mao, Z., Yuan, R., Wang, L., Hu, X., Zhou, F., & Kang, H. (2019). The clinical outcomes of selenium supplementation on critically ill patients: A meta-analysis of randomized controlled trials. Medicine, 98(20), e15473. https://doi.org/10.1097/MD.0000000000015473
Zhao Y, et al. The Clinical Outcomes of Selenium Supplementation On Critically Ill Patients: a Meta-analysis of Randomized Controlled Trials. Medicine (Baltimore). 2019;98(20):e15473. PubMed PMID: 31096444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical outcomes of selenium supplementation on critically ill patients: A meta-analysis of randomized controlled trials. AU - Zhao,Yan, AU - Yang,Mengmeng, AU - Mao,Zhi, AU - Yuan,Rui, AU - Wang,Li, AU - Hu,Xin, AU - Zhou,Feihu, AU - Kang,Hongjun, PY - 2019/5/18/entrez PY - 2019/5/18/pubmed PY - 2019/5/29/medline SP - e15473 EP - e15473 JF - Medicine JO - Medicine (Baltimore) VL - 98 IS - 20 N2 - PURPOSE: Selenium supplementation is a potentially promising adjunctive therapy for critically ill patients, but the results are controversy among studies. Accordingly, we performed this meta-analysis to more clearly detect the efficacy and safety of selenium supplementation on critically ill patients. METHODS: Systematic literature retrieval was carried out to obtain RCTs on selenium supplementation for critically ill patients up to August 2017. Data extraction and quality evaluation of these studies were performed by 2 investigators. Statistical analyses was performed by RevMan 5.3. Trial sequential analysis (TSA) was conducted to control the risks of type I and type II errors and calculate required information size (RIS). RESULTS: Totally 19 RCTs involving 3341 critically ill patients were carried out in which 1694 participates were in the selenium supplementation group, and 1647 in the control. The aggregated results suggested that compared with the control, intravenous selenium supplement as a single therapy could decrease the total mortality (RR = 0.86, 95% CI: 0.78-0.95, P = .002, TSA-adjusted 95% CI = 0.77-0.96, RIS = 4108, n = 3297) and may shorten the length of stay in hospital (MD -2.30, 95% CI -4.03 to -0.57, P = .009), but had no significant treatment effect on 28-days mortality (RR = 0.96, 95% CI: 0.85-1.09, P = .54) and could not shorten the length of ICU stay (MD -0.15, 95% CI -1.68 to 1.38, P = .84) in critically ill patients. Our results also showed that selenium supplementation did not increase incidence of drug-induced side effect compared with the control (RR 1.04, 95% CI 0.83 to 1.30, P = .73). CONCLUSIONS: The current evidence suggests that the use of selenium could reduce the total mortality, and TSA results showed that our outcome is reliable and no more randomized controlled trials are needed. But selenium supplementation might have no effect on reducing 28-days mortality as well as the incidence of new infections, or on length of stay in ICU or mechanical ventilation. However, the results should be used carefully because of potential limitations. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/31096444/The_clinical_outcomes_of_selenium_supplementation_on_critically_ill_patients:_A_meta_analysis_of_randomized_controlled_trials_ DB - PRIME DP - Unbound Medicine ER -